The Company expects that its cash, cash equivalents and short-term investments as of September 30, 2023, will enable it to fund its operating plan into the fourth quarter of 2025.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CABA:
- Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update
- Cellares, Cabaletta Bio team to evaluate CABA-201 manufacturing on Cell Shuttle
- Cabaletta Bio receives FDA clearance of CABA-201 IND application
- Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in November
- Cantor Fitzgerald biotech analyst holds an analyst/industry conference call